Summary of treatment groups comparing efficacy of systemic or nanoparticle encapsulated venetoclax administered as a single agent or in combination with S63845
| Treatment group . | S63845 dose in mg/kg . | Venetoclax dose in mg/kg . | No. of doses per week . | Total S63845 dose in mg/kg . | Total venetoclax dose in mg/kg . | Number of mice with measurable tumors on day 20 . |
|---|---|---|---|---|---|---|
| Venetoclax | 0 | 25 | 3 | 0 | 150 | 7 of 7 |
| S63845 | 12.5 | 0 | 3 | 75 | 0 | 7 of 7 |
| Venetoclax | 0 | 25 | 3 | 0 | 150 | 7 of 7 |
| S63845+ venetoclax | 12.5 | 25 | 3 | 75 | 150 | 7 of 7 |
| S63845+ venetoclax-NP | 12.5 | 25 | 3 | 75 | 150 | 0 of 7 |
| S63845+ venetoclax | 25 | 100 | 5 | 250 | 1000 | 0 of 7 |
| Treatment group . | S63845 dose in mg/kg . | Venetoclax dose in mg/kg . | No. of doses per week . | Total S63845 dose in mg/kg . | Total venetoclax dose in mg/kg . | Number of mice with measurable tumors on day 20 . |
|---|---|---|---|---|---|---|
| Venetoclax | 0 | 25 | 3 | 0 | 150 | 7 of 7 |
| S63845 | 12.5 | 0 | 3 | 75 | 0 | 7 of 7 |
| Venetoclax | 0 | 25 | 3 | 0 | 150 | 7 of 7 |
| S63845+ venetoclax | 12.5 | 25 | 3 | 75 | 150 | 7 of 7 |
| S63845+ venetoclax-NP | 12.5 | 25 | 3 | 75 | 150 | 0 of 7 |
| S63845+ venetoclax | 25 | 100 | 5 | 250 | 1000 | 0 of 7 |